Establishment of a primary pleomorphic xanthoastrocytoma cell line: In vitro responsiveness to some chemotherapeutics

Neurosurgery

Volumn 70, Issue 1, 2012, Pages 188-197

  Bagriacik, Emin Umit ^a   Baykaner, Mustafa Kemali ^a   Yaman, Melek ^a   Sivrikaya, Gizem ^a   Durdaǧ, Emre ^a   Emmez, Hakan ^a   Fincan, Gökcxe Öztürk ^a   Börcek, Alp Özgün ^a   Secxen, Ahmet Eren ^a   Ercan, Sevim ^a  

^a GAZI UNIVERSITY   (Turkey)

Author keywords

Anticancer chemotherapy; Brain tumors; Cell culture; Confocal microscopy

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ANTINEOPLASTIC AGENT; DOXORUBICIN; LIMESTONE; THYMIDINE; TRIMETREXATE;

ADOLESCENT; ARTICLE; ASTROCYTOMA; CANCER GRADING; CASE REPORT; CELL GROWTH; CLINICAL FEATURE; CONCENTRATION RESPONSE; CONFOCAL MICROSCOPY; CYTOTOXICITY; DRUG SENSITIVITY; FOLLOW UP; GAMMA KNIFE RADIOSURGERY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MALE; NEUROLOGIC EXAMINATION; PLEOMORPHIC XANTHOASTROCYTOMA; PRIMARY CELL CULTURE; PRIORITY JOURNAL;

ADOLESCENT; ANTINEOPLASTIC AGENTS; ASTROCYTOMA; BRAIN NEOPLASMS; CELL COUNT; CELL PROLIFERATION; DRUG SCREENING ASSAYS, ANTITUMOR; GLIAL FIBRILLARY ACIDIC PROTEIN; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; PRIMARY CELL CULTURE; TETRAZOLIUM SALTS; THIAZOLES; THYMIDINE; TRITIUM; TUMOR CELLS, CULTURED;

EID: 84856112632     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1227/NEU.0b013e3182262c5b     Document Type: Article

References (46)

1. Allegranza A, Ferraresi S, Bruzzone M, Giombini S. Cerebromeningeal pleomorphic xanthoastrocytoma. Report on four cases: clinical, radiologic and pathological features (Including a case with malignant evolution). Neurosurg Rev. 1991;14(1):43-49.
2. Fouladi M, Jenkins J, Burger P, et al. Pleomorphic xanthoastrocytoma: favorable outcome after complete surgical resection. Neuro Oncol. 2001;3(3):184-192. (Pubitemid 33674110)
3. Lal PG, Ghirnikar RS, Eng LF. Astrocyte-astrocytoma cell line interactions in culture. J Neurosci Res. 1996;440(4):216-222. (Pubitemid 26134411)
4. Rutka JT, Smith SL. Transfection of human astrocytoma cells with glial fibrillary acidic protein complementary DNA: analysis of expression, proliferation, and tumorigenicity. Cancer Res. 1993;53(15):3624-3631. (Pubitemid 23229647)
5. Glasser RS, Rojiani AM, Mickle JP, Eskin TA. Delayed occurrence of cerebellar pleomorphic xanthoastrocytoma after supratentorial pleomorphic xanthoas-trocytoma removal. Case report. J Neurosurg. 1995;82(1):116-118.
6. Grant JW, Gallagher PJ. Pleomorphic xanthoastrocytoma. Immunohistochemical methods for differentiation from fibrous histiocytomas with similar morphology. Am J Surg Pathol. 1986;10(5):336-341. (Pubitemid 16038744)
7. Herpers MJ, Freling G, Beuls EA. Pleomorphic xanthoastrocytoma in the spinal cord. Case report. J Neurosurg. 1994;80(3):564-569. (Pubitemid 24073023)
8. Kros JM, Vecht CJ, Stefanko SZ. The pleomorphic xanthoastrocytoma and its differential diagnosis: a study of five cases. Hum Pathol. 1991;22(11):1128- 1135.
9. Powell SZ, Yachnis AT, Rorke LB, Rojiani AM, Eskin TA. Divergent differen¬tiation in pleomorphic xanthoastrocytoma. Evidence for a neuronal element and possible relationship to ganglion cell tumors. Am J Surg Pathol. 1996;20(1):80-85. (Pubitemid 26007713)
10. de Tella OI Jr, Herculano MA, Prandini MN, Stavale JN, Aguiar PH. Malignant transformation of pleomorphic xanthoastrocytoma: case report. Arq Neuropsiquiatr. 2003;61(1):104-106. (Pubitemid 36396170)
11. Hamlat A, Le Strat A, Guegan Y, Ben-Hassel M, Saikali S. Cerebellar pleo-morphic xanthoastrocytoma: case report and literature review. Surg Neurol. 2007;68(1):89-95.
12. Doolittle ND, Petrillo A, Bell S, Cummings P, Eriksen S. Blood-brain barrier disruption for the treatment of malignant brain tumors: the National Program. J Neurosci Nurs. 1998;30(2):81-90.
13. Kroll RA, Neuwelt EA. Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means. Neurosurgery. 1998;42(5):1083-1100. (Pubitemid 28196521)
14. Kroll RA, Pagel MA, Muldoon LM, Roman-Goldstein S, Fiamengo SA, Neuwelt EA. Improving drug delivery to intracerebral tumor and surrounding brain in a rodent model: a comparison of osmotic versus bradykinin modification of the blood-brain and/or blood-tumor barriers. Neurosurgery. 1998;43(4):879-889.
15. Antonelli A, Ferrari SM, Fallahi P, et al. Primary cell cultures from anaplastic thyroid cancer obtained by fine-needle aspiration used for chemosensitivity tests. Clin Endocrinol (Oxf). 2008;69(1):148-152. (Pubitemid 351847276)
16. Maniwa Y, Yoshimura M, Takata M, Nishimura Y, Ohno Y. Effective chemo¬therapy based on a chemosensitivity test for malignant pleural mesothelioma. Ann Thorac Cardiovasc Surg. 2008;14(5):319-321.
17. Ugurel S, Schadendorf D, Pföhler C, et al. Dermatologic Cooperative Oncology Group. In vitro drug sensitivity predicts response and survival after individualized sensitivity-directed chemotherapy in metastatic melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group. Clin Cancer Res. 2006;12(18):5454-5463. (Pubitemid 44497261)
18. Samson DJ, Seidenfeld J, Ziegler K, Aronson N. Chemotherapy sensitivity and resistance assays: a systematic review. J Clin Oncol. 2004;22:3618-3630. (Pubitemid 41103669)
19. Schrag D, Garewal HS, Burstein HJ, Samson DJ, Von Hoff DD, Somerfield MR. American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays. J Clin Oncol. 2004;22(17):3631-3638. (Pubitemid 41103670)
20. Grippo MC, Penteado PF, Carelli EF, Cruz-Höfling MA, Verinaud L. Estab¬lishment and partial characterization of a continuous human malignant glioma cell line: NG97. Cell Mol Neurobiol. 2001;21(4):421-428. (Pubitemid 34001149)
21. Miller TA, Smith GS, Banan A, Kokoska ER. Cytoskeleton as a target for injury in damaged intestinal epithelium. Microsc Res Tech. 2000;51(2):149-155.
22. Efferth T, Konkimalla VB, Wang YF, et al. Prediction of broad spectrum resistance of tumors towards anticancer drugs. Clin Cancer Res. 2008;14(8):2405-2412. (Pubitemid 351551074)
23. Korshunov A, Golanov A. Pleomorphic xanthoastrocytomas: immunohisto-chemistry, grading and clinic-pathologic correlations. An analysis of 34 cases from a single institute. J Neurooncol. 2001;52(1):63-72. (Pubitemid 32544660)
24. Marton E, Feletti A, Orvieto E, Longatti P. Malignant progression in pleomorphic xanthoastrocytoma: personal experience and review of the literature. J Neurol Sci. 2007;252(2):144-153. (Pubitemid 46048646)
25. Tekkök IH, Sav A. Anaplastic pleomorphic xanthoastrocytomas. Review of the literature with reference to malignancy potential. Pediatr Neurosurg. 2004;40(4): 171-181. (Pubitemid 40082215)
26. Giannini C, Scheithauer BW, Burger PC, et al. Pleomorphic xanthoastrocytoma: what do we really know about it? Cancer. 1999;85(9):2033- 2045. (Pubitemid 29202780)
27. Van Roost D, Kristof R, Zentner J, Wolf HK, Schramm J. Clinical, radiological, and therapeutic features of pleomorphic xanthoastrocytoma: report of three patients and review of the literature. J Neurol Neurosurg Psychiatry. 1996;60(6):690-692. (Pubitemid 26237125)
28. Cartmill M, Hewitt M, Walker D, Lowe J, Jaspan T, Punt J. The use of chemotherapy to facilitate surgical resection in pleomorphic xanthoastrocytoma: experience in a single case. Child's Nerv Syst. 2001;17(9):563-566. (Pubitemid 32842716)
29. Ono A, Kanno H, Hayashi A, et al. Collagen gel matrix assay as an in vitro chemosensitivity test for malignant astrocytic tumors. Int J Clin Oncol. 2007;12(2): 125-130. (Pubitemid 46632461)
30. Im SH, Chung CK, Kim SK, Cho BK, Kim MK, Chi JG. Pleomorphic xan-thoastrocytoma: a developmental glioneuronal tumor with prominent glioproli-ferative changes. J Neuro Oncol. 2004;66(1-2):17-27. (Pubitemid 38258356)
31. Asano K, Miyamoto S, Kubo O, Kikkukawa T, Yagihashi A, Ohkuma H. A case of anaplastic pleomorphic xanthoastrocytoma presenting with tumor bleeding and cerebrospinal fluid dissemination. Brain Tumor Pathol. 2006;23(1):55-63. (Pubitemid 44576312)
32. Goncharova EA, Lim P, Goncharov DA, Eszterhas A, Panettieri RA Jr, Krymskaya VP. Assays for in vitro monitoring of proliferation of human airway smooth muscle (ASM) and human pulmonary arterial vascular smooth muscle (VSM) cells. Nat Protoc. 2006;1(6):2905-2908.
33. Hofer S, Herrmann R. Chemotherapy for malignant brain tumors of astrocytic and oligodendroglial lineage. J Cancer Res Clin Oncol. 2001;127(2):91-95.
34. Schiff D. Temozolomide and radiation in low-grade and anaplastic gliomas: temoradiation. Cancer Invest. 2007;25(8):776-784. (Pubitemid 350223169)
35. Brock CS, Newlands ES, Wedge SR, et al. Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res. 1998;58(19):4363-4367. (Pubitemid 28450038)
36. Dhodapkar M, Rubin J, Reid JM, et al. Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer. Clin Cancer Res. 1997;3(7):1093-1100. (Pubitemid 27319755)
37. Yung WK. Temozolomide in malignant gliomas. Semin Oncol. 2000;27 (3 suppl 6): 27-34. (Pubitemid 30390232)
38. Friedman HS, Kerby T, Calvert H. Temozolomide and treatment of malignant glioma. Clin Cancer Res. 2000;6(7):2585-2597. (Pubitemid 30482092)
39. Koukourakis GV, Kouloulias V, Zacharias G, et al. Temozolomide with radiation therapy in high grade brain gliomas: pharmaceuticals considerations and efficacy; a review article. Molecules. 2009;14(4):1561-1577.
40. Newlands ES, Foster T, Zaknoen S. Phase I study of temozolamide (TMZ) combined with procarbazine (PCB) in patients with gliomas. Br J Cancer. 2003;89(2):248-251. (Pubitemid 36976310)
41. Mihaliak AM, Gilbert CA, Li L, et al. Clinically relevant doses of chemotherapy agents reversibly block formation of glioblastoma neurospheres. Cancer Lett. 2010;296(2):168-177.
42. Baker SD, Wirth M, Statkevich, P, et al. Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer. Clin Cancer Res. 1999;5(2):309-317. (Pubitemid 29085183)
43. Spiro TP, Liu L, Majka S, Haaga J, Willson JK, Gerson SL. Temozolomide: the effect of once-and twice-a-day dosing on tumor tissue levels of the DNA repair protein O(6)-alkylguanine-DNA-alkyltransferase. Clin Cancer Res. 2001;7(8):2309-2317. (Pubitemid 32751629)
44. Ostermann S, Csajka C, Buclin T, et al. Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clin Cancer Res. 2004;10(11):3728-3736. (Pubitemid 38697606)
45. Blakeley J, Portnow J. Microdialysis for assessing intratumoral drug disposition in brain cancers: a tool for rational drug development. Expert Opin Drug Metab Toxicol. 2010;6(12):1477-1491.
46. Agarwala SS, Kirkwood JM. Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma. Oncologist. 2000;5(2):144-151. (Pubitemid 30238234)